Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate

A new approach to the treatment of cancer is suggested, based on the innate overproduction of hydrogen peroxide in cancer cells. Hydrogen peroxide serves as a prodrug in the presence of transition metal ions, such as iron delivered by ferrocene. Under the effect of ferrocene, hydrogen peroxide is sp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacy and pharmacology Vol. 59; no. 11; pp. 1549 - 1553
Main Authors: Wlassoff, Wjatschesslaw A., Albright, Craig D., Sivashinski, Michael S., Ivanova, Anastasia, Appelbaum, Jacob G., Salganik, Rudolph I.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-11-2007
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new approach to the treatment of cancer is suggested, based on the innate overproduction of hydrogen peroxide in cancer cells. Hydrogen peroxide serves as a prodrug in the presence of transition metal ions, such as iron delivered by ferrocene. Under the effect of ferrocene, hydrogen peroxide is split into hydroxyl anions and highly reactive hydroxyl radicals. The latter cause oxidative DNA damage, which induces apoptosis, leading to elimination of cancer cells. Tamoxifen, a drug that interacts with oestrogen receptors, was used as a carrier to deliver ferrocene to breast cancer cells. For this aim tamoxifen conjugated to ferrocene (Tam‐Fer) was synthesized. We have shown that the frequency of apoptotic events in MCF‐7 breast cancer cells treated with Tam‐Fer is significantly higher than in cells treated with tamoxifen or ferrocene separately. The increase of apoptosis correlates well with the rise in generation of reactive oxygen species in cancer cells. These results show that the hydrogen peroxide overproduced in tumour cells can serve as a prodrug for the treatment of cancer.
Bibliography:ArticleID:JPHP1692
istex:75E321686806F0E2CEF4D36976CF0E9CDE999251
ark:/67375/WNG-G2G5DTWV-R
Biomedical Research Center, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield S1 1WB UK
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3573
2042-7158
DOI:10.1211/jpp.59.11.0013